Development of an attenuated strain of chikungunya virus for use in vaccine production

Levitt, Neil H.; Ramsburg, Helen H.; Hasty, Sherman E.; Repik, Patricia M.; Cole, Francis E.; Lupton, H W

doi:10.1016/0264-410x(86)90003-4

Cited by 220 publications

(205 citation statements)

References 10 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…RNAi, for example, is emerging as a new strategy to fight virus infections [46,47,48]. There is currently no commercial vaccine for Chikungunya virus, although some candidate vaccines have been tested in humans [49,50]. For a complete review of the vaccine studies performed in the past 40 years against CHIKV, see Levit et al [50].…”

Section: Treatment and Vaccinationmentioning

confidence: 99%

Chikungunya: an emerging and spreading arthropod-borne viral disease.

Cavrini

Gaibani

Pierro

et al. 2009

J Infect Dev Ctries

View full text Add to dashboard Cite

The virus causing Chikungunya disease was identified over 50 years ago; however, because the disease appeared only in developing countries, little research on it has been done. Research interest in the disease increased after an important epidemiological outbreak occurred in 2005 on the French metropolitan island of La Reunion located in the south-eastern part of the Indian Ocean. In 2007, a smaller outbreak of Chikungunya developed in the north-eastern part of Italy made possible by immigration of a viremic patient from the Indian Ocean area and the enormous population of Aedes albopictus in Italy. Currently, Chikungunya is spreading in Southeast Asian aspects, clinical pictures, diagnosis and treatment of the disease caused by Chikungunya virus.

show abstract

Section: Treatment and Vaccinationmentioning

confidence: 99%

Chikungunya: an emerging and spreading arthropod-borne viral disease.

Cavrini

Gaibani

Pierro

et al. 2009

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…The current live vaccine (Lot 1-85, TSI-GSD-218) was developed at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and was produced at the Salk Institute, Swiftwater, PA, from a lot of the GMK-passaged strain 15561 inactivated vaccine by subsequent serial passage in MRC-5 cells. 23 The live vaccine proved to be safe and immunogenic in a phase I trial in 15 alphavirus-naive volunteers. 21 The current phase II, randomized, double-blind, placebo-controlled trial was designed to provide additional safety and immunogenicity data for live CHIK vaccine TSI-GSD-218.…”

Section: Introductionmentioning

confidence: 99%

“…21 The current phase II, randomized, double-blind, placebo-controlled trial was designed to provide additional safety and immunogenicity data for live CHIK vaccine TSI-GSD-218. 22,23 The CHIK vaccine elicited neutralizing antibody and protected mice and monkeys against challenge. 23 The vaccine was shown to be safe and immunogenic in humans in phase I trials 21 (Malinowski FJ, unpublished data).…”

Section: Introductionmentioning

confidence: 99%

“…22,23 The CHIK vaccine elicited neutralizing antibody and protected mice and monkeys against challenge. 23 The vaccine was shown to be safe and immunogenic in humans in phase I trials 21 (Malinowski FJ, unpublished data). The placebo was MRC-5 tissue culture fluid manufactured concurrently with the CHIK vaccine, and diluted identically as the CHIK vaccine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Edelman¹,

Tacket²,

Wasserman³

et al. 2000

The American Journal of Tropical Medicine and Hygiene

283

229

View full text Add to dashboard Cite

Abstract. We conducted a phase II, randomized, double-blind, placebo-controlled, safety and immunogenicity study of a serially passaged, plaque-purified live chikungunya (CHIK) vaccine in 73 healthy adult volunteers. Fiftynine volunteers were immunized one time subcutaneously with the CHIK vaccine and 14 were immunized with placebo (tissue culture fluid). Vaccinees were clinically evaluated intensively for one month, and had repeated blood draws for serological assays (50% plaque-reduction neutralization test) for one year. Except for transient arthralgia in five CHIK vaccinees, the number and severity of local and systemic reactions and abnormal laboratory tests after immunization were similar in CHIK vaccinees and placebo recipients. Fifty-seven (98%) of 58 evaluable CHIK vaccinees developed CHIK neutralizing antibody by day 28, and 85% of vaccinees remained seropositive at one year after immunization. No placebo recipients seroconverted. This promising live vaccine was safe, produced well-tolerated side effects, and was highly immunogenic.

show abstract

“…This vaccine was created from a CHIKV isolate from Thailand and passaged in human lung cells (MRC-5) to generate an attenuated virus .This resulted in a virus that produced smaller plaques compared to the parental virus. In humans, this vaccine proved to be highly immunogenic, but also caused arthralgia in some of the vaccines (27,72).…”

Section: Live-attenuated Vaccinesmentioning

confidence: 99%

Global epidemiology of Zika and Chikungunya virus human infections

et al. 2017

View full text Add to dashboard Cite

Zika virus was discovered in 1947. The first reported case of Zika fever was in a sentinel rhesus monkey in Uganda in 1947, while the first human cases were reported in Nigeria in 1954. Since the first evidence of human infection, Zika was active in several countries in Africa and Asia, as sporadic cases and serological evidence of Zika human infections have been demonstrated in several reports. The outbreak of Zika in Yap Island in 2007 is considered the first emergency of this infection. Since then Zika has spread worldwide with a large ongoing epidemic in South and Central America. A huge concern nowadays is about the relationship between Zika infection and microcephaly and about the sexual transmission of the virus. The first identified outbreak of Chikungunya human infection, with an incidence estimated at 23%, was reported from July 1952 to March 1953 in the Southern Province of the current Tanzania. Since then Chikungunya circulated mainly in continental Africa with limited outbreaks. The virus started to spread east bound involving most of the areas surroundings the Indian Ocean. In 2004/2005 a large outbreak developed in La Reunion a French territory in the Indian Ocean: from this point Chikungunya spread to India and from there, due a viraemic traveller returning from Kerala, to Italy where in the summer of 2007 the first outbreak with local viral transmission in a temperate climate zone occurred. In the following years Chikungunya moved to the Caribbean and South America. Recently also the USA experienced the spread of this virus and a limited outbreak based again on local spreading occurred in the French Department of Var, in August 2017.

show abstract

Development of an attenuated strain of chikungunya virus for use in vaccine production

Cited by 220 publications

References 10 publications

Chikungunya: an emerging and spreading arthropod-borne viral disease.

Chikungunya: an emerging and spreading arthropod-borne viral disease.

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Global epidemiology of Zika and Chikungunya virus human infections

Contact Info

Product

Resources

About